Consultation on a draft Global action plan to address antimicrobial resistance
|
|
- Francis Morris
- 5 years ago
- Views:
Transcription
1 Consultation on a draft Global action plan to address antimicrobial resistance The questionnaire is divided into four sections. The questions are broadly framed and intended to give you the opportunity to enter into some depth and explain your organization's viewpoint. While only questions marked with * are mandatory, we would appreciate answers to as many as possible. Where a choice of answer needs to be selected please highlight your answer. Before answering the questions, please refer to our list of supporting documents. About you Name of individual respondent* Philip Howard 2. address* (preference for official addresses) 3. Are you authorised to represent your organization or interest group?* Yes 4. Organization Name* Joint response from Royal Pharmaceutical Society UK Clinical Pharmacy Association - Pharmacy Infection Network, 5. Address of the organization* Royal Pharmaceutical Society, 1 Lambeth High Street, London SE1 7JN. UK UK Clinical Pharmacy Association - Pharmacy Infection Network, 1st Floor, Publicity House, 59 Long Street, Wigston, Leicester LE18 2AJ, UK 6. Organization website (if available) and 7. Country* United Kingdom 8. Type of Organization* Other (please specify) - both professional associations. RPS is the professional leadership body for pharmacists in the UK. UKCPA is a professional association for clinical pharmacy in the UK 9. Main sector of interest Human health 10. Would you like to be added to our mailing list to receive updates on the development of the global action plan?* Yes Page 1
2 General questions 1. From the perspective of your organization, what are the most important areas of concern in AMR? From the perspective of pharmacy organisations, the major areas of concern are: Increasing antimicrobial resistance to existing agents. The lack of existing pipeline of new antibacterial agents, and the lack of access to antibiotics already available elsewhere in the world Access to antibiotics without prescription (using left over antibiotics or buying antibiotics). Patients not taking antibiotics as prescribed (not completing the course) The lack of availability of pharmaceutical quality antibiotics and the use of counterfeit antibiotics across all parts of the world. Over use of antibiotics, but especially broad spectrum agents Point of Care or rapid diagnostics for discrimination between bacterial/viral infections and for selection of appropriate agent Development of alternatives to antibiotics Ensure priority funding for antimicrobial research and development and stimulation of governmental incentives to improve the business case for new antimicrobial agents? Lack of research/trials in general for antimicrobial stewardship Clinical trials with primary endpoint of non-inferiority not helpful in placing new agents Need better dosing/pk information for current agents and those new to market especially in vulnerable patients e.g. obese, renal/hepatic dysfunction Better access to therapeutic drug monitoring results in real time for antibiotics requiring monitoring to optimise treatment Better information on antimicrobial consumption across the world 2. Is your organization currently involved in work related to AMR? Yes Both the UKCPA-PIN and RPS are closely involved in the development and establishment of antimicrobial stewardship. Pharmacist members of the UKCPA-PIN and RPS are fully integrated into key NHS advisory groups who develop policy and guidance relating to antimicrobial usage in the UK Page 2
3 RPS is working jointly with the other medical and nursing Royal Colleges in organising a summit in November 2014 to engage all professions in delivering the UK 5 Year Antimicrobial Resistance Strategy. RPS also works closely with the UK media to help share accurate messages to the public on AMR. The RPS has made a commitment to tackle AMR in its New Medicines Guide- A guide to Science Underpinning Pharmaceutical Practice (May 2014) UKCPA-PIN delivers education and training, and professional support to antimicrobial pharmacists in the UK and elsewhere in the world. They have developed an educational curriculum for antimicrobial pharmacists. Members of both help support the UK government bodies to develop antimicrobial stewardship standards for hospitals and community. Questions about the draft global action plan outline document Before the WHA resolution was adopted, two WHO AMR Strategic Technical Advisory Group (STAG) meetings were held in anticipation, which included members plus a large number of representatives from other organizations. These meetings identified key issues, concerns and led to the development of a draft outline. As this consultation progresses and stakeholder meetings are held, the secretariat will harvest and incorporate the input into the draft global action plan. 1. How would you rate your understanding of WHO s intention in the development of a global action plan to address AMR? Fair Additional comments The UK focus has mainly been on the delivery of the UK 5 Year Antimicrobial Resistance Strategy. 2. From the perspective of your organization, are the major issues relating to AMR outlined in the draft global action plan? Yes If No, what additional issues need to be addressed? Questions on the Building blocks described in the draft outline. You will notice, the global action plan has been constructed around building blocks in recognition that different countries will have different starting points. In this situation, countries can choose building blocks to concentrate upon. Each building block specified has been identified as a key area where specific attention, planning and work are needed to achieve progress in addressing AMR. Page 3
4 Through questions in this section, we would like to hear your opinions on these building blocks in more detail. I. Building block-1: Increasing awareness and understanding about AMR and of the actions and changes needed Improving public and healthcare professional understanding and awareness of AMR, and the role they can play in minimising its spread through improved infection prevention (hygiene and vaccination). Public Engagement Activities: There needs to be a fresh way of communicating a message that people have heard before and are getting wary of. We need to make it clear that bacteria are becoming resistant to antimicrobials, and not themselves who are resistant. Patients only taking antibiotics prescribed for them, and to complete the course. Decreasing antimicrobial prescribing, especially broad spectrum antibiotics. Public and healthcare professionals to understand that antimicrobial resistance is not just observed in antibacterials, but extends to antifungals antivirals and biocides (which may lead to crossresistance). Monitoring antimicrobial use and resistance in the veterinary and food sectors with a coherent message on the impact on human health and delivery of a clear action plan on antimicrobial stewardship Stakeholders: General Medical Council (GMC) (Stewardship), Advisory Committee on Antimicrobial Resistance (SACAR) Antibiotic Resistance Coordination Group (DEFRA DARC) (food/veterinary) ACMSF Antimicrobial Resistance (AMR) Working Group. Public Health England, European Centres for Disease Control, European Medicines Agency (EMA) Government agencies (NHS in UK) working closely with the media play an important role in highlighting AMR to the public. Target driven goals need to be set to drive better but less antibiotic prescribing. c) What steps have already been taken to address this priority? In the UK, antimicrobial stewardship guidelines exist for hospitals (Start Smart then Focus) and primary care (TARGET) In addition, antibiotic prescribing competencies and antimicrobial stewardship also exist. petencies 2_.pdf Page 4
5 There is a 5 year Antimicrobial Resistance Strategy (2013-8) for the UK In Europe, there has been an educational programme for schoolchildren on hygiene, infections and antibiotics Specifically for Antimicrobial Stewardship, we would like to see a worldwide definition of AMS and it components, and a recommendation for its implementation. A definition with 2 years, implemented in the developed world by 5 years, and the developing world by 10 years. For public and healthcare awareness, a partnership approach between WHO and global partners to deliver messages through all media formats. Local funding is often a barrier to effective communication. Do once in multiple languages and share. This could be achieved within 2 years for the major world languages. A measurement such as the Eurobarometer would identify if any progress has been made. A single repository of information for all healthcare professionals and the public to access needs to be established within 2 years. II. Building block-2: Identifying the most important approaches for preventing development of infections and the steps needed to move beyond guidance to more effective implementation of such approaches Improvements in personal hygiene, improving availability of clean water, and increasing vaccination uptake. Availability of counterfeit medicines. A lack of availability of sufficient healthcare professionals to oversee appropriate distribution of antibiotics and vaccines. Understanding the epidemiology of spread of resistant organisms. Again, governmental lead to improve hygiene and vaccination uptake through clearer messages through the media and national vaccination programmes with targets. Support to the developing world to provide clean water and improved sanitation, and better education on infection prevention and control. Global actions required: Introduction or revision of antimicrobial resistance, epidemiology and importance of hygiene and vaccination in curricula of medicine, veterinary, pharmacy and nursing undergraduate programmes Continuing professional development and training of qualified medical, veterinary, pharmacy and nursing staff Page 5
6 c) What significant work has already been done to address this? UK immunisation programme Control of antibiotics as food additives banned in EU Development of national frameworks for the integrated monitoring of antibiotic use, with measurement of infection control indicators in both primary and secondary care and cross-sector detection of emerging pathogens within 2 years. III. Building block-3: Optimizing the use of existing antimicrobials for human and animal health and in agriculture Over use of antibiotics in humans without prescription, animal husbandry for food promotion, and agriculture for preventing crop destruction. Lack of availability of pharmaceutical grade antibiotics for treatment especially in developing countries. Counterfeit medicines which contain low doses on antibiotics which are probably more dangerous than no antibiotic at all. Development of rapid methods for detection of pathogen, discrimination between bacterial / viral / fungal infections and rapid point of care diagnostics and technologies for detecting the appropriate (if any) antimicrobial agent. National legislation to ensure that antibiotics are only prescribed for humans and animals (singular or herd) by prescription from an authorised practitioner. Enforcement of pharmaceutical legislation to stop the use of counterfeit medicines through tightening the supply chain. If we are to fully control the whole process, then a single convention on antibiotics, similar to the 1961 United Nation Convention on Narcotics would allow global control. This will be difficult to achieve, particularly due to different requirements in different parts of the world such as the developing world where the availability of health professionals is low and alternative methods of antibiotic. c) What steps have already been taken to address this priority? European legislation in 2006 for antibiotics for humans and animals to require a prescription. No routine use of antibiotics as growth promoters in food production. Introduction of AMS guidance as in 1c and 1d above in the UK. Page 6
7 Apart from those stated in block 1, an international convention on antibiotics within 5 years is essential. IV. Building block-4: Identifying and closing critical gaps in knowledge needed to address AMR A proper understanding of what the public understands about AMR so as to better target messages. Understanding (through highlighting emerging research in the area and formulation of a coherent response to key stakeholder and public engagement) the role of biocides (used in the domestic, veterinary, food sectors) in the contribution of antimicrobial resistance Research funded by continental or national governments to identify the levers needed to change public reliance on antibiotics. c) What steps have already been taken to address this priority? Outside of Eurobarometer surveys of public knowledge of AMR and antibiotic use, there has been research done in this area. However, in the UK, government has made available specific research funding streams specifically antimicrobial resistance and stewardship within the 5 year antimicrobial stewardship. The UK government has taken evidence on antimicrobial resistance from experts in the scientific, medical and veterinary fields. The outcome is still awaited. Research to be funded and completed with 2 years on what tools and techniques improve the public understanding of AMR and use or requesting of antibiotics. Level of funding for research, measurement of research outcome and measurement of impact (translation of basic research to changing policy etc) V. Building block-5: Developing an innovative and sustainable approach to develop and distribute critical products and technologies needed to address AMR Lack of diagnostics that can be used in real time in the clinic or pharmacy to determine susceptibility to particular antibiotics. Page 7
8 Lack of rapid diagnostics to rapidly identify whether infections are viral or bacterial infection across ALL patient populations. Lack of technology to measure concentrations of antibiotics at the sight of infection, especially in a real-time manner. Lack of global tracking of antimicrobials to minimise the opportunity for counterfeit antimicrobials to be distributed and used. Use of similar classes of antibiotics in humans, animals and agriculture that might increase resistance in critical drugs. Lack of equal access to new or existing agents at the same time across the world. Need for faster access through global licensing of new antimicrobials. Clinical trials for new antimicrobials need to address all patient groups where they are likely to be used eg. Very young children to the very old; those with severe renal or hepatic dysfunction; obese patients. Ideally not non-inferiority trials. A global convention on antibiotics needs to be agreed to help the enforcement of licensing and distributing of antimicrobials for all human, animal and agriculture use. The relevant agencies need to get the engagement of world leaders to make this happens. Major funding investment is required to develop new technologies and to make them available globally in affordable way. Development of national and international consensus on a business case for new antimicrobials which brings together a number of national proposals including controversial measures such as de-linking of sales and profits, to remove market-driven overuse of new and existing antibiotics. d) What steps have already been taken to address this priority? Some initial work has been done to improve the licensing processes between the EMA and FDA. The Longitude Prize 2014 in the UK is offering 10 million to create a cheap, accurate, rapid and easy-to-use point of care test kit for bacterial infections. The Wellcome Trust has spotlighted antimicrobial resistance for investment. Many grants are now available to find alternatives to antibiotics. Global convention on antimicrobials within 5 years, but ideally within 2 years. Investment in new antibiotics, antimicrobials and technologies within 2 years. Page 8
9 VI. Building block-6: Assessing the long term economic, developmental and social costs and implications of AMR as a basis for sustainable investment and action Antimicrobial resistance is already having an impact in the UK with some patients with ESBLs needing to be admitted to hospital for treatment, rather than receive treatment in the community. We are seeing increased lengths of stays in hospital, more time in ITU and higher antibiotics costs. This is in a background of the NHS trying to save 20 billion over 3 years. We are not clear what the current or future impact of AMR will be in the UK, but it will only continue to grow year on year. Again, national governments need to fund research to assess the local national health and societal costs of AMR, and build the current and potential costs into future funding. c) What steps have already been taken to address this priority? The Wellcome Trust is working with the UK Government to look at the economic impact of AMR. Assessment of economic impact of AMR within 2 years at national and global level. Re-assessment at 5 years. Concluding questions 3. What contribution would your organization be able to make in implementing the global action plan? RPS has made a commitment in the New Medicines Guide for Pharmacists in the UK: Recommendation 2 - Improving Antimicrobial Stewardship and Stimulating New Antimicrobial Development Educate the public and patients on the use of antimicrobials and their place in therapy Encourage further development of antimicrobial stewardship by healthcare professionals to maintain the effectiveness of current and any future antimicrobials. Support the discovery and development of new antimicrobials or treatment methods by developing new financial incentives. The UKCPA-PIN has started working closely with other Pharmacy Antimicrobial Stewardship organisations from around the world to share learning and to increase AMS across the globe. Page 9
10 Both the RPS and UKCPA-PIN would be happy to work with WHO on the GAP either directly, or through the International Pharmaceutical Federation ( ). 4. Additional input that you feel would facilitate development of the GAP. None. All stated above. Page 10
National Action Plan development support tools
National Action Plan development support tools Sample Checklist This checklist was developed to be used by multidisciplinary teams in countries to assist with the development of their national action plan
More informationConsultation on a draft Global action plan to address antimicrobial resistance
Consultation on a draft Global action plan to address antimicrobial resistance The questionnaire is divided into four sections. The questions are broadly framed and intended to give you the opportunity
More informationJoint Statement on Antimicrobial Resistance
Joint Statement on Antimicrobial Resistance The UK Faculty of Public Health (FPH), the Royal College of Physicians (RCP), the Royal Pharmaceutical Society (RPS), the Royal College of Nursing (RCN) and
More informationWould you like to be added to our mailing list to receive updates on the development of the global action plan?* Y X N
Would you like to be added to our mailing list to receive updates on the development of the global action plan?* Y X N Yes. General questions 1. From the perspective of your organization, what are the
More informationREPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT
1 REPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT The Department of Health organised a summit on Antimicrobial Resistance (AMR) the purpose of which was to bring together all stakeholders involved
More informationDevelopment and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics
Priority Topic B Diagnostics Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics The overarching goal of this priority topic is to stimulate the design,
More informationResolution adopted by the General Assembly on 5 October [without reference to a Main Committee (A/71/L.2)]
United Nations A/RES/71/3 General Assembly Distr.: General 19 October 2016 Seventy-first session Agenda item 127 Resolution adopted by the General Assembly on 5 October 2016 [without reference to a Main
More informationAntimicrobial Resistance, yes we care! The European Joint Action
Antimicrobial Resistance, yes we care! The European Joint Action Context of the Joint Action General objectives Inclusive governance Conclusion Context of the Joint Action 1. Context of this Joint Action
More informationCouncil of the European Union Brussels, 13 June 2016 (OR. en)
Council of the European Union Brussels, 13 June 2016 (OR. en) 9952/16 SAN 241 AGRI 312 VETER 58 NOTE From: To: General Secretariat of the Council Council No. prev. doc.: 9485/16 SAN 220 AGRI 296 VETER
More informationComments from The Pew Charitable Trusts re: Consultation on a draft global action plan to address antimicrobial resistance September 1, 2014
Comments from The Pew Charitable Trusts re: Consultation on a draft global action plan to address antimicrobial resistance September 1, 2014 The Pew Charitable Trusts is an independent, nonprofit organization
More informationDraft ESVAC Vision and Strategy
1 2 3 7 April 2016 EMA/326299/2015 Veterinary Medicines Division 4 5 6 Draft Agreed by the ESVAC network 29 March 2016 Adopted by ESVAC 31 March 2016 Start of public consultation 7 April 2016 End of consultation
More informationCOPING WITH ANTIMICROBIAL RESISTANCE
JANUARY 2018 COPING WITH ANTIMICROBIAL RESISTANCE REPORT 2 Friends of Europe January 2018 This is truly a global problem that can only be addressed by working together across the planet Tamsin Rose Senior
More informationGlobal Strategies to Address AMR Carmem Lúcia Pessoa-Silva, MD, PhD Antimicrobial Resistance Secretariat
Global Strategies to Address AMR Carmem Lúcia Pessoa-Silva, MD, PhD Antimicrobial Resistance Secretariat EMA Working Parties with Patients and Consumers Organisations (PCWP) and Healthcare Professionals
More informationCanada s Activities in Combatting Antimicrobial Resistance. Presentation to the JPIAMR Management Board March 29, 2017
Canada s Activities in Combatting Antimicrobial Resistance Presentation to the JPIAMR Management Board March 29, 2017 AMR in Canada Surveillance data indicates that rates of infection for some resistant
More informationANTIMICROBIAL RESISTANCE and causes of non-prudent use of antibiotics in human medicine in the EU
ANTIMICROBIAL RESISTANCE and causes of non-prudent use of antibiotics in human medicine in the EU Health and Food Safety John Paget (NIVEL) Dominique Lescure (NIVEL) Ann Versporten (University of Antwerp)
More informationAntimicrobial resistance: the challenges for animal health
Elisabeth Erlacher Vindel Deputy Head of the Scientific and Technical Departement World Organisation for Animal Health (OIE) Antimicrobial resistance: the challenges for animal health Rabat, 17 Feb. 2015
More informationModels for stewardship in Hospital - UK Models Philip Howard Consultant Antimicrobial Pharmacist
Models for stewardship in Hospital - UK Models Philip Howard Consultant Antimicrobial Pharmacist philip.howard2@nhs.net Twitter: @AntibioticLeeds United Kingdom of England, Scotland, Wales & Northern Ireland
More informationPromoting One Health : the international perspective OIE
Promoting One Health : the international perspective OIE Integrating Animal Health & Public Health: Antimicrobial Resistance SADC SPS Training Workshop (Animal Health) 29-31 January 2014 Gaborone, Botwana
More informationTable Of Content. Dutch EU Presidency Conference on Antimicrobial Resistance... 2 Summary... 3 Work Package... 8
Table Of Content Dutch EU Presidency Conference on Antimicrobial Resistance... 2 Summary... 3 Work Package... 8 Conference... 8 Coordinator, Leader contact and partners... 9 Outputs... 10 Final report...
More informationAustralia s response to the threat of antimicrobial resistance
Australia s response to the threat of antimicrobial resistance Professor Warwick Anderson AM Chief Executive Officer National Health and Medical Research Council Australia s health system Antimicrobial
More informationHighlights on Hong Kong Strategy and Action Plan on Antimicrobial Resistance ( ) (Action Plan)
香港藥學會 The Pharmaceutical Society of Hong Kong Kowloon G.P.O. Box 73552, Yau Ma Tei, Kowloon, Hong Kong Society s Fax: (852) 2376-3091 E-mail: pharmacist@pshk.hk Websites: http://pshk.hk Highlights on Hong
More informationAntimicrobial Resistance Update for Community Health Services
Antimicrobial Resistance Update for Community Health Services Elizabeth Beech Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England October 2015 elizabeth.beech@nhs.net Superbugs
More informationPrudent use of antimicrobial agents Dairy Sector Initiatives. Robin Condron Dairy Australia
Prudent use of antimicrobial agents Dairy Sector Initiatives Robin Condron Dairy Australia INTERNATIONAL DAIRY FEDERATION Our mission To represent the dairy sector as a whole at international level, by
More informationRequest for advice on the impact on public health and animal health of the use of antibiotics in animals
Request for advice on the impact on public health and animal health of the use of antibiotics in animals Animal Health Advisory Committee 22 March 2013 Mario Nagtzaam, SANCO D6 Political commitments as
More informationSECOND REPORT FROM THE COMMISSION TO THE COUNCIL
SECOND REPORT FROM THE COMMISSION TO THE COUNCIL ON THE BASIS OF MEMBER STATES REPORTS ON THE IMPLEMENTATION OF THE COUNCIL RECOMMENDATION (2002/77/EC) ON THE PRUDENT USE OF ANTIMICROBIAL AGENTS IN HUMAN
More informationEuropean Medicines Agency role and experience on antimicrobial resistance
European Medicines Agency role and experience on antimicrobial resistance Regional Training Workshop on Antimicrobial Resistance (AMR) Responding to the global challenge of AMR threats: toward a one health
More informationEU strategy to fight against Antimicrobial Resistance
EU strategy to fight against Antimicrobial Resistance OECD workshop on the Economics of Antimicrobial Use in the Livestock Sector and Development of Antimicrobial Resistance Paris, 12 October 2015 Martial
More informationCombating Antimicrobial Resistance: A Manufacturing Perspective
Combating Antimicrobial Resistance: A Manufacturing Perspective Steve Brooks VP, EHS Pfizer Inc & Chair, Environmental Work Group of the AMR Industry Alliance June 20 th 2017 AMR - Environmental Matters
More informationStrategy 2020 Final Report March 2017
Strategy 2020 Final Report March 2017 THE COLLEGE OF VETERINARIANS OF ONTARIO Introduction This document outlines the current strategic platform of the College of Veterinarians of Ontario for the period
More informationOIE Resolution and activities related to the Global Action Plan. Regional Seminar for OIE National Focal Points for Veterinary Products 4 th Cycle
Dr Elisabeth Erlacher Vindel Deputy Head of the Scientific and Technical Departement World Organisation for Animal Health (OIE) OIE Resolution and activities related to the Global Action Plan Regional
More informationThe South African Antimicrobial Resistance Strategy Framework
The South African Antimicrobial Resistance Strategy Framework Adrian Brink Clinical Microbiologist, Ampath National Laboratory Services, Milpark Hospital, Johannesburg Introduction Global call for action
More informationAntimicrobial Stewardship in Food Animals in Canada AMU/AMR WG Update Forum 2016
Antimicrobial Stewardship in Food Animals in Canada AMU/AMR WG Update Forum 2016 What is Antimicrobial Stewardship? Conserving the effectiveness of existing treatments through infection prevention and
More informationOECD WORK ON AMR: TACKLING THE NEGATIVE CONSEQUENCES OF ANTIBIOTIC RESISTANCE ON HUMAN HEALTH. Michele Cecchini OECD Health Division
OECD WORK ON AMR: TACKLING THE NEGATIVE CONSEQUENCES OF ANTIBIOTIC RESISTANCE ON HUMAN HEALTH Michele Cecchini OECD Health Division Antimicrobial Resistance is a Global Threat Modern medicine and surgery
More informationConsultation on a draft Global action plan to address antimicrobial resistance
Consultation on a draft Global action plan to address antimicrobial resistance The questionnaire is divided into four sections. The questions are broadly framed and intended to give you the opportunity
More informationPfizer Position on Antimicrobial Resistance Management. Kirill Tverskoy, Medical Director Pfizer Russia February 21, 2017
Pfizer Position on Antimicrobial Resistance Management Kirill Tverskoy, Medical Director Pfizer Russia February 21, 2017 Objectives and Trends of Nowadays Healthcare Environment Effective and innovative
More informationCouncil Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting
COUNCIL OF THE EUROPEAN UNION Council Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting Luxembourg, 10 June 2008 The Council adopted
More informationAntimicrobial Resistance Direction Statement for Animals and Plants, and Work Programme
Antimicrobial Resistance Direction Statement for Animals and Plants, and Work Programme MPI Discussion Paper No: 2016/10 ISBN No: 978-1-77665-185-0 (online) ISSN No: 2253-3907 (online) February 2016 Disclaimer
More informationAntimicrobial Resistance at human-animal interface in the Asia-Pacific Region
Antimicrobial Resistance at human-animal interface in the Asia-Pacific Region Gyanendra Gongal Scientist International Health and Regulations Health Security and Emergency Response WHO South-East Asia
More informationPan-Canadian Action Plan on Antimicrobial Resistance and Antimicrobial Use
Pan-Canadian Action Plan on Antimicrobial Resistance and Antimicrobial Use Lindsay Noad Public Health Agency of Canada (PHAC) November 29 th, 2017 Purpose To provide an update on the development of the
More informationAntimicrobial Stewardship: The South African Perspective
Antimicrobial Stewardship: The South African Perspective Precious Matsoso Director General; National Department of Health; South Africa 13 th November 2015 Why do we need an AMR strategy and implementation
More informationAmerican Veterinary Medical Association
A V M A American Veterinary Medical Association 1931 N. Meacham Rd. Suite 100 Schaumburg, IL 60173-4360 phone 847.925.8070 800.248.2862 fax 847.925.1329 www.avma.org March 31, 2010 Centers for Disease
More informationAntimicrobial Resistance and Dentistry. LDC Officials Day 4 December 2015 Susie Sanderson
Antimicrobial Resistance and Dentistry LDC Officials Day 4 December 2015 Susie Sanderson Who am I? Why are we interested in AMR? Where is the leadership? Who is taking action? What is the BDA doing? Is
More informationThe South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa
The South African AMR strategy 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa Background to AMR 2 What is Antimicrobial stewardship and
More informationThe UK strategy for antimicrobial resistance (AMR) and its implications for research and development
The UK strategy for antimicrobial resistance (AMR) and its implications for research and development John Watson Deputy Chief Medical Officer Department of Health Thursday 3 April 2014 1 The UK Antimicrobial
More informationOIE Regional Commission for Europe Regional Work Plan Framework Version adopted during the 85 th OIE General Session (Paris, May 2017)
OIE Regional Commission for Europe Regional Work Plan Framework 2017-2020 Version adopted during the 85 th OIE General Session (Paris, May 2017) Chapter 1 - Regional Directions 1.1. Introduction The slogan
More informationNAP on AMR: Singapore
FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14
More informationQUESTIONNAIRE FOR ADMINISTRATIONS [1], ASSOCIATIONS AND OTHER ORGANISATIONS
Contribution ID: bc4cbd4d-288c-4560-ad81-59ea4ecd4d5d Date: 19/04/2017 16:02:09 QUESTIONNAIRE FOR ADMINISTRATIONS, ASSOCIATIONS AND OTHER ORGANISATIONS Public Consultation on possible activities under
More informationBacteria become resistant to antibiotics- not humans or animals.
July 2017 Dear Colleague, World Antibiotic Awareness Week - National Community Pharmacy Public Health Campaign 2017 Please find enclosed information and resources for the next contractual national community
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 22 December 2005 COM (2005) 0684 REPORT FROM THE COMMISSION TO THE COUNCIL ON THE BASIS OF MEMBER STATES REPORTS ON THE IMPLEMENTATION OF THE COUNCIL RECOMMENDATION
More informationANTIMICROBIAL RESISTANCE: GLOBAL BURDEN
ANTIMICROBIAL RESISTANCE: GLOBAL BURDEN What is AMR? Why is it increasing? What is the scale of the problem? What is the impact? What regions will be most affected? i Burden?^^ DR LIZ TAYLER AMR SECRETARIAT
More informationVeterinary antimicrobials: state of play and future developments 2013 European Medicines Agency/IFAH- Europe Info Day 7-8 March 2013
Veterinary antimicrobials: state of play and future developments 2013 European Medicines Agency/IFAH- Europe Info Day 7-8 March 2013 Mario Nagtzaam, SANCO D6 Political commitments as to addressing AMR
More informationHow to get senior hospital and clinical engagement
How to get senior hospital and clinical engagement Professor Alison Holmes Professor of Infectious Diseases Director, NIHR Health Protection Research Unit: HCAI and AMR Engagement through Organisational
More informationQUESTIONNAIRE FOR ADMINISTRATIONS [1], ASSOCIATIONS AND OTHER ORGANISATIONS
Contribution ID: 6945a24b-2a9b-4774-af54-ad925a28f304 Date: 25/04/2017 11:02:44 QUESTIONNAIRE FOR ADMINISTRATIONS, ASSOCIATIONS AND OTHER ORGANISATIONS Public Consultation on possible activities under
More informationSpeaking notes submitted by Dr. Duane Landals. on behalf of the Canadian Veterinary Medical Association (CVMA)
339, rue Booth Street Ottawa (Ontario) K1R 7K1 t (800) 567-2862 f (613) 236-9681 admin@cvma-acmv.org Speaking notes submitted by Dr. Duane Landals on behalf of the Canadian Veterinary Medical Association
More informationJaipur Declaration on Antimicrobial Resistance
Jaipur Declaration on Antimicrobial Resistance We, the Health Ministers of Member States of the WHO South-East Asia Region participating in the Twenty-ninth Health Ministers Meeting in Jaipur, India, appreciate
More informationThird Global Patient Safety Challenge. Tackling Antimicrobial Resistance
Geneva 12 th -13 th March 2009 Day 1, 12 th March Third Global Patient Safety Challenge Tackling Antimicrobial Resistance Edward Kelly, Coordinator, WHO Patient Safety Programme welcomed all participants
More informationImplementing Antibiotic Stewardship in Rural and Critical Access Hospitals
National Center for Emerging and Zoonotic Infectious Diseases Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals Denise Cardo, MD Director, Division of Healthcare Quality Promotion,
More informationDr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health
Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health Regional Workshop for National Focal Points for Veterinary Products
More informationThe European AMR Challenge - strategic views from the human perspective -
The European AMR Challenge - strategic views from the human perspective - World Health Organization Regional Office for Europe Dr Danilo Lo Fo Wong Senior Adviser on Antimicrobial Resistance Division of
More informationIntroduction to antimicrobial resistance
Introduction to antimicrobial resistance Philip Howard Consultant Antimicrobial Pharmacist HCAI and AMR Project Lead 4 th March 2015 What is antimicrobial resistance? Antibacterials either kill or stop
More informationStratégie et action européennes
Résistance aux antibiotiques : une impasse thérapeutique? Implications nationales et internationales Stratégie et action européennes Dominique L. Monnet, Senior Expert and Head of Disease Programme Antimicrobial
More informationThe trinity of infection management: United Kingdom coalition statement
* The trinity of infection management: United Kingdom coalition statement This coalition statement, on behalf of our organizations (the UK Sepsis Trust, Royal College of Nursing, Infection Prevention Society,
More informationGlobal Communication on AMR in Animal Health: Tripartite and OIE Efforts
Catherine Bertrand-Ferrandis Head of the Communication Unit Taylor Gabourie AMR Communications Officer Global Communication on AMR in Animal Health: Tripartite and OIE Efforts Marrakech, Morocco 29 31
More informationUse of Antibiotics in Animals. A European Perspective by a Dutch observer. Dr. Albert Meijering
Use of Antibiotics in Animals A European Perspective by a Dutch observer Dr. Albert Meijering IPPE, Atlanta, January 30, 2013 Use of antibiotics in animal production: Excessive Injudicious Where does it
More informationPan-Canadian Framework and Approach to Antimicrobial Resistance. Presentation to the TATFAR Policy Dialogue September 27, 2017
Pan-Canadian Framework and Approach to Antimicrobial Resistance Presentation to the TATFAR Policy Dialogue September 27, 2017 PURPOSE Purpose To provide TATFAR members with an overview of Canada s coordinated
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY REFERENCES: MALTA, COUNTRY VISIT AMR. STOCKHOLM: ECDC; DG(SANTE)/
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health and food audits and analysis REFERENCES: ECDC, MALTA, COUNTRY VISIT AMR. STOCKHOLM: ECDC; 2017 DG(SANTE)/2017-6248 EXECUTIVE SUMMARY
More informationOptions for a global development and stewardship framework to combat AMR Consultation of Member States and relevant partners
Options for a global development and stewardship framework to combat AMR Consultation of Member States and relevant partners Geneva, 29 February 2016 Peter Beyer Resolution WHA68.7 Requests the to develop
More informationEvaluation of EU strategy to combat AMR
Evaluation of EU strategy to combat AMR Advisory Group of the Food Chain 30 April 2015 Martial Plantady Legislative officer DDG2.G4: Food, Alert Systems & Training DG Health and Food Safety Antimicrobial
More informationTEXTS ADOPTED Provisional edition. P8_TA-PROV(2018)0429 Animal welfare, antimicrobial use and the environmental impact of industrial broiler farming
European Parliament 204-209 TEXTS ADOPTED Provisional edition P8_TA-PROV(208)0429 Animal welfare, antimicrobial use and the environmental impact of industrial broiler farming European Parliament resolution
More informationWorld Organisation for Animal Health
World Organisation for Animal Health 2017 Progressive Actions for Achievement of global health security Dr Susan Corning BA MSc BVSc MRCVS FRSPH Global Health Security Agenda Steering Group Meeting Geneva,
More information2016/LSIF/FOR/004 Policies to Promote Patient Access to Innovative Treatments and Combat Antimicrobial Resistance
2016/LSIF/FOR/004 Policies to Promote Patient Access to Innovative Treatments and Combat Antimicrobial Resistance Submitted by: Merck Sharp & Dohme Policy Forum on Strengthening Surveillance and Laboratory
More informationTHE GOVERNMENT OF FIJI FIJI NATIONAL ANTIMICROBIAL RESISTANCE ACTION PLAN
THE GOVERNMENT OF FIJI FIJI NATIONAL ANTIMICROBIAL RESISTANCE ACTION PLAN 2015 2 TABLE OF CONTENTS Foreword... 4 Acknowledgments... 5 Acronyms... 6 Introduction... 7 Summary of country situational analysis
More informationOIE strategy on AMR and the Prudent Use of Antimicrobials
Dr. Jocelyn Mérot OIE Sub-Regional Representation for North Africa OIE strategy on AMR and the Prudent Use of Antimicrobials 14th JPC REMESA 19-20 July 2017 Naples (Italy) The OIE Strategy on AMR and the
More informationA European One Health Action Plan against Antimicrobial Resistance (AMR)
A European One Health Action Plan against Antimicrobial Resistance (AMR) CONTENTS 1 1.1 1.2 2 2.1 2.2 2.3 2.4 2.5 3 3.1 3.2 3.3 3.4 3.5 3.6 4 4.1 4.2 4.3 4.4 5 6 THE NEED FOR EU ACTION AGAINST ANTIMICROBIAL
More informationOIE Strategy on Antimicrobial Resistance and the need for new diagnostic tools
Dr Elisabeth Erlacher-Vindel Head Science and New Technologies Department OIE Strategy on Antimicrobial Resistance and the need for new diagnostic tools 12 th OIE SEMINAR 18 th WAVLD, Sorrento (Italy),
More informationOIE AMR Strategy, One Health concept and Tripartite activities
Dr Mária Szabó Chargée de mission OIE AMR Strategy, One Health concept and Tripartite activities Training Seminar for Middle East Focal Points for Veterinary Products Beirut, Lebanon 2017 Summary OIE strategy
More informationImpact of NHS England Quality Indicators on Antimicrobial Resistance. Professor Alan Johnson National Infection Service Public Health England
Impact of NHS England Quality Indicators on Antimicrobial Resistance Professor Alan Johnson National Infection Service Public Health England A Risk Assessment of Antibiotic Pan-Drug Resistance in the UK:
More informationManaging AMR at the Human-Animal Interface. OIE Contributions to the AMR Global Action Plan
Managing AMR at the Human-Animal Interface OIE Contributions to the AMR Global Action Plan 6th Asia-Pacific Workshop on Multi-Sectoral Collaboration for the Prevention and Control of Zoonoses Dr Susan
More informationRESPONSIBLE ANTIMICROBIAL USE
RESPONSIBLE ANTIMICROBIAL USE IN THE CANADIAN CHICKEN AND TURKEY SECTORS VERSION 2.0 brought to you by: ANIMAL NUTRITION ASSOCIATION OF CANADA CANADIAN HATCHERY FEDERATION CANADIAN HATCHING EGG PRODUCERS
More informationInitiatives for Addressing Antimicrobial Resistance in the Environment. Executive Summary
Initiatives for Addressing Antimicrobial Resistance in the Environment Executive Summary This executive summary highlights key themes from a scientific white paper and discussion at the International Environmental
More information2017 EU Action Plan against AMR state of play of implementation One-Health Network on AMR 26 October Brussels
2017 EU Action Plan against AMR state of play of implementation One-Health Network on AMR 26 October 2018 - Brussels Aurélien PEREZ, DG Health and Food Safety Political context European level e.g. September
More informationQUESTIONNAIRE FOR ADMINISTRATIONS [1], ASSOCIATIONS AND OTHER ORGANISATIONS
Contribution ID: 1a70194f-a127-4ca3-947b-68e324381166 Date: 03/04/2017 16:00:14 QUESTIONNAIRE FOR ADMINISTRATIONS, ASSOCIATIONS AND OTHER ORGANISATIONS Public Consultation on possible activities under
More informationWHO's View on IVDs for Addressing AMR
WHO's View on IVDs for Addressing AMR Francis Moussy, Ph.D. Lead for AMR Diagnostics Secretary, SAGE IVD 19 June 2017 1 World Health Assembly 2015 the global action plan sets out five strategic objectives:
More informationAntibiotic stewardship Implementing Strategies
2 nd Joint Conference on the Antimicrobial Resistance Action Plan (AMRAP) and the Strategy for the Control of Antimicrobial Resistance in Ireland (SARI) 1. Background Antibiotic stewardship Implementing
More informationQUESTIONNAIRE FOR ADMINISTRATIONS [1], ASSOCIATIONS AND OTHER ORGANISATIONS
Contribution ID: eb78a906-8b33-4cbe-a9a3-d0720e7cd318 Date: 18/04/2017 18:16:34 QUESTIONNAIRE FOR ADMINISTRATIONS, ASSOCIATIONS AND OTHER ORGANISATIONS Public Consultation on possible activities under
More informationEU Action Plan to combat the rising threats from Antimicrobial Resistance: State of play
EU Action Plan to combat the rising threats from Antimicrobial Resistance: State of play Rosa M. Peran i Sala Policy Officer AMR Coordination EC Action Plan against AMR Animal Health Advisory Committee
More informationUK Five Year AMR Strategy ( ) Cheshire & Merseyside Health Protection CPD Event Tuesday 19 th November 2013
UK Five Year AMR Strategy (2013-18) Tuesday 19 th November 2013 Antimicrobial Resistance (AMR) Why AMR: Impact on society The rapid spread of multi-drug resistant (MDR) Many existing antimicrobials are
More informationIFMSA Policy Proposal Antimicrobial Resistance
IFMSA Policy Proposal Antimicrobial Resistance Proposed by Team of Officials Presented to the IFMSA General Assembly March Meeting 2017 in Arusha, Tanzania Policy Statement Introduction Antimicrobial resistance
More informationQuestions and Answers on the Community Animal Health Policy
MEMO/07/365 Brussels, 19 September 2007 Questions and Answers on the Community Animal Health Policy 2007-13 Why has the Commission developed a new Community Animal Health Policy (CAHP)? The EU plays a
More informationOverview of Canada's Federal Actions to Address Antimicrobial Resistance and Antibiotic Stewardship
Overview of Canada's Federal Actions to Address Antimicrobial Resistance and Antibiotic Stewardship Jacqueline Arthur, RN, BScN Centre for Communicable Diseases and Infection Control Commonwealth Laboratory
More informationPerspective on AnA Global timicrobial Resistance
National Center for Emerging and Zoonotic Infectious Diseases Perspective on AnA Global timicrobial Resistance Dawn M. Sievert, PhD, MS Associate Director for Antimicrobial Resistance Division of Foodborne,
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018
7 December 2017 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018 Chairpersons Chair: D. Murphy Status Adopted in December
More informationinternational news RECOMMENDATIONS
The Third OIE Global Conference on Veterinary Education and the Role of the Veterinary Statutory Body was held in Foz do Iguaçu (Brazil) from 4 to 6 December 2013. The Conference addressed the need for
More informationEuropean Antibiotic Awareness Day: Promoting prudent antibiotic use in Europe
European Antibiotic Awareness Day: Promoting prudent antibiotic use in Europe Dominique L. Monnet, Head of Disease Programme, Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Joint
More informationGovernment Initiatives to Combat Antimicrobial Resistance (AMR)
Government Initiatives to Combat Antimicrobial Resistance (AMR) in the Philippines Ma. Virginia G. Ala, MD, MPH, CESO III Director IV and Program Manager National Center for Pharmaceutical Access and Management,
More informationFAO-OIE-WHO Tripartite Positions and Actions on Antimicrobial Resistance (AMR)
FAO-OIE-WHO Tripartite Positions and Actions on Antimicrobial Resistance (AMR) Patrick Otto, FAO, Rome On behalf of the FAO/OIE/WHO Tripartite Technical Focal Points Context 2 Global demand for food security
More informationOverview of the OIE PVS Pathway
Overview of the OIE PVS Pathway Regional Seminar for OIE National Focal Points for Animal Production Food Safety Hanoi, Vietnam, 24-26 June 2014 Dr Agnes Poirier OIE Sub-Regional Representation for South-East
More informationWHO perspective on antimicrobial resistance
WHO perspective on antimicrobial resistance Bernadette Abela-Ridder, DVM, MSc, PhD Global Foodborne Infections Network (GFN) Coordinator Department of Food Safety and Zoonoses (FOS) 1 Overview of presentation
More informationR E S O U R C E S T O O L K I T F O R H E A L T H C A R E P R O F E S S I O N A L S A N D P R O F E S S I O N A L B O D I E S I N E N G L A N D
R E S O U R C E S T O O L K I T F O R H E A L T H C A R E P R O F E S S I O N A L S A N D P R O F E S S I O N A L B O D I E S I N E N G L A N D All resources and materials are available via http://bit.ly/eaad2014
More informationDr Marc Sprenger Director Antimicrobial Resistance Secretariat Global action plan on antimicrobial resistance
Global Action Plan on Antimicrobial Resistance Dr Marc Sprenger Director Antimicrobial Resistance Secretariat When are we entering the post-antibiotic era? For some diseases we have already entered! Fatal
More information